Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Acquir Immune Defic Syndr ; 85(4): 454-457, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-33136744

RESUMO

BACKGROUND: Pre-exposure prophylaxis (PrEP) is only effective in preventing new HIV infections when taken consistently. In clinical practice, asking a patient about their adherence (self-report) is the predominant method of assessing adherence to PrEP. Although inexpensive and noninvasive, self-report is subject to social desirability and recall biases. Several clinical trials demonstrate a discrepancy between self-reported adherence and biomarker-based recent adherence. Less is known about the accuracy of self-report in real-world clinical settings. This brief report addresses this knowledge gap and describes the concordance between self-reported adherence and biomarker-based adherence in real-world clinical settings. METHODS: A liquid chromatography-mass spectrometry urine test for tenofovir was developed and used clinically to detect recent nonadherence (no dose in at least 48 hours) for each individual. Two clinics' standard operating procedures recommend utilization of the urine-based adherence test for patients who self-report that they are not struggling with adherence. Those who self-report struggling with adherence receive enhanced adherence support without the need for additional testing. The number of results indicating recent nonadherence from these 2 clinics were analyzed to assess the concordance between self-reported adherence and biomarker-based adherence. RESULTS: Across 2 clinics, 3987 tests were conducted from patients self-reporting as "adherent," and 564 [14.1%; 95% confidence interval (CI): 13.1% to 15.2%] demonstrated recent nonadherence with the liquid chromatography-mass spectrometry test. At clinic #1 in Florida, 3200 tests were conducted, and 465 (14.5%; 95% CI: 13.3% to 15.8%) demonstrated recent nonadherence. At clinic #2 in Texas, 787 tests were conducted, and 99 (12.6%; 95% CI: 10.4% to 14.9%) demonstrated recent nonadherence. CONCLUSIONS: Utilization of biomarker-based adherence monitoring at these 2 clinics resulted in 564 additional patients receiving enhanced adherence support who otherwise would not have been identified as nonadherent to their prescribed PrEP regimen. These findings suggest that objective adherence monitoring can be used clinically to enable providers to identify nonadherent patients and allocate support services accordingly.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/sangue , Infecções por HIV/tratamento farmacológico , HIV-1 , Adesão à Medicação , Autorrelato , Adulto , Biomarcadores/urina , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
2.
AIDS Care ; 31(10): 1203-1206, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-30821473

RESUMO

Maximizing the impact of HIV pre-exposure prophylaxis (PrEP) requires optimizing access and adherence for those at risk of contracting HIV. This study examined challenges to the processes of accessing and adhering to PrEP encountered by participants from a large, U.S. urban clinical center and assessed the utility of objectively monitoring PrEP adherence via urine. Most participants (65%) reported starting PrEP within 1-3 months of hearing about it, although 35% of participants encountered a provider unwilling to prescribe PrEP. Self-reported adherence was high among this population, with remembering to take the medication reported as the major barrier to adherence (44%) rather than cost or stigma. Urine tenofovir (TFV) monitoring was highly acceptable to this population, and participants indicated greater willingness to undergo urine monitoring every 3 months compared to finger prick (dried blood spot), phlebotomy, or hair follicle testing. These findings highlight the importance of focusing efforts toward reducing obstacles to PrEP use and support the use of urine TFV adherence monitoring as a marker of PrEP adherence.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/urina , Infecções por HIV/prevenção & controle , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Adesão à Medicação/psicologia , Profilaxia Pré-Exposição , Tenofovir/administração & dosagem , Adolescente , Adulto , Fármacos Anti-HIV/uso terapêutico , Centros Comunitários de Saúde , Feminino , Humanos , Masculino , Percepção , Philadelphia , Profilaxia Pré-Exposição/métodos , Profilaxia Pré-Exposição/estatística & dados numéricos , Tenofovir/uso terapêutico , Tenofovir/urina , População Urbana , Adulto Jovem
4.
J Int Assoc Provid AIDS Care ; 14(2): 103-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25331226

RESUMO

In 2012, the US Food and Drug Administration approved Truvada as a pre-exposure prophylaxis (PrEP) for adults at risk of HIV. PrEP is highly effective at preventing HIV when taken daily, but no gold standard exists for consistently administering PrEP to populations at highest risk. The "I Am Men's Health" program used an innovative methodology to generate adherence to PrEP in 23 mostly young men who have sex with men of color (yMSMc), during a 28-week period from February to September 2013. Adherence was measured using weekly medication pickup rates. The average age of the participants was 21 years, and the majority were black and lived below the poverty line. Time on PrEP ranged from 1 to 28 weeks (2723 person-days), and the weighted average adherence was 73%. The methodology used in this study was preliminarily effective at generating adherence to PrEP among high-risk yMSMc in a community setting and may help inform large-scale future HIV prevention interventions.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Desoxicitidina/análogos & derivados , Infecções por HIV/prevenção & controle , Infecções por HIV/psicologia , Homossexualidade Masculina/psicologia , Adesão à Medicação , Compostos Organofosforados/administração & dosagem , Adulto , População Negra/psicologia , Desoxicitidina/administração & dosagem , Combinação de Medicamentos , Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Profilaxia Pré-Exposição , Adulto Jovem
6.
J Prim Prev ; 35(2): 93-102, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24259082

RESUMO

Street-based sex-work and poly-substance drug use, coupled with low vaccination rates and limited utilization of the mainstream health care system, put the sex worker communities of Bogotá's city center at extreme risk of infection with the hepatitis B virus (HBV). Vaccination is critical to maintaining low prevalence of the disease and low incidence of new cases, yet the floating and inconsistent nature of Bogotá's drug-involved female and transsexual prostitution communities make it difficult to complete a 3-dose vaccination program. Between December 2011 and March of 2012, the Fénix Foundation collaborated with the Bogotá Health Department to deliver free HBV vaccines to this vulnerable population. This paper outlines methods used in the vaccination program to generate a 37.7% adherence rate, significantly higher than that previously reported for HBV vaccination programs also targeting marginalized populations. This program's practices are based on the Fénix peer leader method, and are offered as a model that can be applied to other health interventions operating in analogous contexts, with similarly high-risk populations.


Assuntos
Acessibilidade aos Serviços de Saúde/organização & administração , Vacinas contra Hepatite B , Adesão à Medicação/psicologia , Trabalho Sexual/psicologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Vacinação , Adulto , Colômbia , Feminino , Promoção da Saúde/organização & administração , Humanos , Masculino , População Urbana , Populações Vulneráveis/psicologia
7.
J Cell Biochem ; 111(5): 1179-87, 2010 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-20717918

RESUMO

Microgravity (µXg) leads to a 10-15% loss of bone mass in astronauts during space flight. Osteoclast (OCL) is the multinucleated bone-resorbing cell. In this study, we used the NASA developed ground-based rotating wall vessel bioreactor (RWV), rotary cell culture system (RCCS) to simulate µXg conditions and demonstrated a significant increase (2-fold) in osteoclastogenesis compared to normal gravity control (Xg). Gene expression profiling of RAW 264.7 OCL progenitor cells in modelled µXg by Agilent microarray analysis revealed significantly increased expression of critical molecules such as cytokines/growth factors, proteases and signalling proteins, which play an important role in enhanced OCL differentiation/function. Transcription factors such as c-Jun, MITF and CREB implicated in OCL differentiation are upregulated; however no significant change in the levels of NFATc1 expression in preosteoclast cells subjected to modelled µXg. We also identified high-level expression of calcium-binding protein, S100A8 (calcium-binding protein molecule A8/calgranulin A) in preosteoclast cells under µXg. Furthermore, modelled µXg stimulated RAW 264.7 cells showed elevated cytosolic calcium (Ca(2+)) levels/oscillations compared to Xg cells. siRNA knock-down of S100A8 expression in RAW 264.7 cells resulted in a significant decrease in modelled µXg stimulated OCL differentiation. We also identified elevated levels of phospho-CREB in preosteoclast cells subjected to modelled µXg compared to Xg. Thus, modelled µXg regulated gene expression profiling in preosteoclast cells provide new insights into molecular mechanisms and therapeutic targets of enhanced OCL differentiation/activation to prevent bone loss and fracture risk in astronauts during space flight missions.


Assuntos
Diferenciação Celular/genética , Perfilação da Expressão Gênica , Osteoclastos/citologia , Ausência de Peso/efeitos adversos , Animais , Astronautas , Reabsorção Óssea/etiologia , Reabsorção Óssea/genética , Reabsorção Óssea/prevenção & controle , Linhagem Celular , Fraturas Ósseas/etiologia , Fraturas Ósseas/genética , Fraturas Ósseas/prevenção & controle , Macrófagos/citologia , Camundongos , Modelos Biológicos , Análise de Sequência com Séries de Oligonucleotídeos , Voo Espacial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...